Ramentaceone
Ramentaceone (7-Methyljuglon), a naphthoquinone that can be isolated from Drosera sp., inhibits PI3K activity. Ramentaceone (7-Methyljuglon) reduces the expression of the PI3K protein and inhibits the phosphorylation of the Akt protein in breast cancer cells. Ramentaceone (7-Methyljuglon) induces apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 14787-38-3
- Formula: C11H8O3
- Molecular Weight:188.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | IC50 |
11.9 μM
Compound: 1
|
Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
|
[PMID: 25059501] |
| HeLa | IC50 |
66.6 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
|
[PMID: 25059501] |
| HL-60 | IC50 |
8.75 μM
Compound: 1, 7-methyljuglone
|
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
|
[PMID: 22250825] |
| HUVEC | ED50 |
5.7 μg/mL
Compound: 9
|
Cytotoxicity against human HUVEC
Cytotoxicity against human HUVEC
|
[PMID: 15270571] |
| KB | ED50 |
4.1 μg/mL
Compound: 9
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15270571] |
| LNCaP | ED50 |
3.7 μg/mL
Compound: 9
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15270571] |
| Lu1 | ED50 |
13.2 μg/mL
Compound: 9
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15270571] |
| MCF7 | IC50 |
27.2 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay
|
[PMID: 25059501] |
| NFF | IC50 |
7.6 μM
Compound: 2
|
Cytotoxicity against human NFF cells assessed as reduction in cell viability after 48 hrs by resazurin dye based assay
Cytotoxicity against human NFF cells assessed as reduction in cell viability after 48 hrs by resazurin dye based assay
|
[PMID: 33314932] |
| PBMC | IC50 |
18.4 μM
Compound: 1
|
Cytotoxicity against human PBMC assessed as cell survival after 24 hrs by XTT assay
Cytotoxicity against human PBMC assessed as cell survival after 24 hrs by XTT assay
|
[PMID: 25059501] |
| Vero | IC50 |
15.1 μg/mL
Compound: 6
|
Cytotoxicity against Vero cells after 48 hrs by XTT method
Cytotoxicity against Vero cells after 48 hrs by XTT method
|
[PMID: 17888665] |
Chemical Information
-
CAS No. 14787-38-3
-
Molecular Weight 188.18
-
Formula C11H8O3
-
SMILES
O=C1C=CC(C2=C1C=C(C)C=C2O)=O
-
Synonyms
7-Methyljuglon
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)